isenmenger syndrome (ES) is characterized by elevated pulmonary vascular resistance and right-to-left shunting through a systemic-to-pulmonary circulation connection. 1 A progressive increase in pulmonary vascular resistance (PVR) leads to right ventricular dysfunction, congestive cardiac failure, and death, usually in the fourth decade. Currently, no drug is routinely used to arrest the progressive increase in PVR and pulmonary artery (PA) pressure in ES patients. The pathological changes in the pulmonary vascular bed in ES patients are similar to those of patients of idiopathic PA hypertension (IPAH). 2 Newer therapies like inhaled nitric oxide and phosphodiesterase-5 (PDE-5) inhibitors have shown a favorable hemodynamic response in patients of IPAH, leading to improvement in symptoms and exercise capacity. [3] [4] [5] [6] In contrast, little evidence is available with these drugs in ES because there is a concern that the vasodilators may worsen hypoxia by decreasing systemic vascular resistance (SVR) in ES. However, PDE-5 inhibitors like sildenafil and tadalafil are preferential pulmonary vasodilators 4, 7 ; hence, the risk of systemic desaturation resulting from a decrease in SVR is unlikely.
Clinical Perspective p 1810

Methods
Sixteen consecutive symptomatic ES patients were enrolled in the study after providing written informed consent. The study was approved by the institutional ethics committee. The diagnosis of ES was based on clinical findings, chest x-ray, ECG, and echocardiographic features. Cardiac catheterization, followed by oxygen study, was used in selected patients to diagnose reversible pulmonary hypertension; such patients were excluded. Severely ill patients (World Health Organization [WHO] class IV), patients with congestive cardiac failure or pulmonary capillary wedge pressure Ͼ15 mm Hg, those with abnormal baseline biochemical profile, patients with atrial fibrillation, and patients with hypersensitivity to PDE-5 inhibitors were excluded. Eleven patients were on stable doses of diuretics. Baseline investigations, ie complete hemogram, kidney function tests, liver function tests, and coagulation profile, were done in all patients.
After assessment of WHO functional class and a 6-minute walk test, the patients were taken for cardiac catheterization study. Under local anesthesia, vascular access was taken by inserting 5F and 7F sheaths in the femoral artery and vein, respectively. A Swan-Ganz catheter was advanced into the PA under fluoroscopic guidance. After the lines were placed, the patients were allowed to rest for 15 minutes, and the following hemodynamic measurements were recorded: systemic arterial pressure, right atrial pressure, PA pressure, pulmonary capillary wedge pressure, and heart rate. All measurements were performed during end expiration, and the mean pressures were calculated as an average over at least 10 beats. Oxygen saturation in the cardiac chambers, PA, systemic veins, and systemic arteries also was estimated.
After the calculation of PVR and SVR and the extent of left-to-right and right-to-left shunts, all patients were given tadalafil (1 mg/kg body weight; maximum, 40 mg). A repeat right-heart catheterization study was performed after 90 minutes. During this period, the patient was kept under constant hemodynamic monitoring, along with systemic arterial oxygen saturation monitoring by pulse oximeter in the catheterization laboratory. After completion of the study, all patients were put on oral tadalafil (maximum dose, 40 mg) under supervision in the hospital. After initiation of therapy, the patients were followed up clinically every 4 weeks and were reassessed after 12 weeks for WHO functional class, exercise capacity (6-minute walk test), and hemodynamic study by cardiac catheterization.
Study End Points
Primary end point was the efficacy and safety of tadalafil in decreasing the absolute PVR at 90 minutes after tadalafil therapy. Patients with a Ն20% decrease in PVR were defined as responders. 8 The secondary end points of the study were the immediate and short-term effects of the drug on SVR, PVR-to-SVR ratio, systemic and pulmonary oxygen saturation, mean systemic and PA pressure, right-to-left shunt, and effective pulmonary blood flow. The short-term clinical effects of the drug on functional class and exercise capacity also were studied.
Statistical Analysis
The results are expressed as meanϮSD or percentages. Repeated-measures ANOVA was used to assess changes over time; paired t tests were used to assess specific changes. A value of PՅ0.05 was considered significant. Stata 9.0 statistical software (College Station, Tex) was used.
The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.
Results
Sixteen consecutive ES patients were included. The baseline characteristics are shown in Table 1 . Nine patients (57%) were male, with age ranging from 13 to 42 years (mean, 25Ϯ8.89 years) and weight ranging from 24 to 65 kg (mean, 41.93Ϯ8.83 kg). Three (18.75%) patients had atrial septal defect, 8 patients (50%) had ventricular septal defect, and 4 patients (25%) had patent ductus arteriosus. All 3 patients with atrial septal defect had large ostium secundum atrial septal defect (3.8, 4, and 4.3 cm, respectively) as assessed by echocardiography. One patient (6.25%) had both atrial and ventricular septal defects. Eleven patients (68.75%) were in WHO functional class II; the rest were in WHO class III (Table 1) .
Hemodynamic Profile
The hemodynamic effects of tadalafil are shown in 
PϽ0.005).
The estimated right-to-left shunt decreased significantly over time, but individual comparisons did not achieve statistical significance (Table 2 ). 
Effect on WHO Functional Class and Exercise Capacity
Adverse Effects
Follow-up was complete with no withdrawals. No significant hemodynamic abnormality was observed after tadalafil administration. None of the patients, including nonresponders, showed worsening of systemic arterial oxygen saturation. No adverse events were noted during the 12-week study period.
Discussion
The primary finding of this study is that a single daily dose of tadalafil is a potent and preferential pulmonary vasodilator that produces a significant decrease in PVR in selected ES patients. Apart from a significant decrease in PVR immediately, all the responders showed a further decrease in PVR over the 12-week period, resulting in a significant decrease in the right-to-left shunt and further improvement in the systemic arterial oxygen saturation than that obtained immediately (Figure) . Furthermore, the nonresponders did not show any increase in PVR or worsening of systemic oxygen saturation at 12 weeks compared with baseline. There are no studies available to date on the hemodynamic effects of PDE-5 inhibitors in patients with ES. In vitro studies of human PA have shown that there is abundance of PDE-5 in lung vascular smooth muscle, 9 which provides a strong molecular basis for PDE-5 inhibitor in the treatment of pulmonary hypertension. PDE-5 inhibitors cause relaxation of pulmonary vascular smooth muscles by activating large-conductance, calcium-activated potassium channels. 5 In IPAH patients, the PDE-5 inhibitors have been shown to reduce mean PA pressure and the pulmonary-to-systemic vascular resistance ratio, resulting in improved ventilation-perfusion mismatch, arterial oxygenation, and functional capacity. 4 However, ES patients have traditionally been excluded from trials of IPAH. Studies of PDE-5 inhibitors in PA hypertension that included a small number of patients with ES have reported a similar beneficial effect in these patients. 5, 7 The effects of the drug on the hemodynamics, systemic arterial oxygen saturation, and exercise capacity in individual patients with ES are not available, however. Hence, PDE-5 inhibitors are still not used to manage patients with ES on the pretext that even a small decrease in the SVR would increase the right-to-left shunt and thus worsen the systemic hypoxia. 10 In the present study, there was a significant increase in effective pulmonary blood flow and mean systemic arterial oxygen saturation after tadalafil administration that resulted from preferential pulmonary vasodilation. None of the patients, including the nonresponders, showed any worsening of systemic oxygen saturation. This can be explained by the preferential distribution of the PDE-5 enzyme, which is located primarily in lungs and penis. 11 Sildenafil is a short-acting PDE-5 inhibitor that has been studied extensively in patients with IPAH. [4] [5] [6] 12 However, its short half-life (4 hours) mandates frequent daily administration. 13 Tadalafil has a half-life of Ϸ18 hours and requires once-daily administration. 11 Hence, using tadalafil may improve patient compliance and reduce treatment cost. The pharmacotherapeutic studies of tadalafil have shown that the maximum vasodilatory effect with tadalafil occurs at 90 minutes in humans. 11 Therefore, in our study, we measured the postdrug hemodynamic effect at 90 minutes.
In our study, the maximum dose of tadalafil that was tolerated was 40 mg. Initially, in 2 nonresponders, a repeat hemodynamic study was done after 1 week with 60 mg of tadalafil (the maximum dose used until now in studies of IPAH 7 ). Both patients remained nonresponders. Furthermore, on initiating therapy with 60 mg tadalafil, both patients complained of severe gastroesophageal reflux; the dose was decreased to 40 mg, which was well tolerated.
Although the present study is a small, single-center study, our results are in agreement with the results of studies of PDE-5 inhibitors in patients with IPAH. This can be explained by the fact that the pathology in the pulmonary vascular bed in patients with ES is similar to that in patients with IPAH. 2 Although the exact mechanism involved in the hemodynamic improvement in patients of IPAH who have predominantly fixed pulmonary vascular obstructive lesions 14 is not known, it has been suggested that reverse remodeling of pulmonary vascular changes as a result of the antiproliferative effects of PDE-5 inhibitors 15 may be responsible.
Early observations of the effects of bosentan on systemic oxygen saturations and echocardiographic parameters in ES are encouraging 16 and are similar to those observed in IPAH. In a recently a, b, and c, Change in PVR, right-to-left shunt, and systemic oxygen saturation after tadalafil therapy after 90 minutes and at 12 weeks vs baseline in all patients. Bold line indicates the mean values.
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reported placebo-controlled trial, bosentan has been shown to improve exercise capacity and hemodynamics without compromising the peripheral oxygen saturation. 17 Observing the favorable hemodynamic effect of tadalafil on the pulmonary vascular bed and on the systemic arterial oxygen saturation, we can infer that the drug may produce improvements in symptoms and exercise capacity in this subgroup of patients with PA hypertension, as has already been documented in patients with IPAH. Further studies are needed, however, to establish the role of PDE-5 inhibitors in ES.
Study Limitations
This was a nonrandomized study without a control group. Although all patients, including the nonresponders, showed improvement in functional class and exercise capacity (which might be due to the placebo effect), a double-blind, placebo-controlled trial should be undertaken to assess the effect of the drug on exercise capacity and functional status. Furthermore, the use of assumed oxygen consumption to calculate PVR and SVR may have altered the absolute values, but the changes in PVR and SVR immediately and in the short term after tadalafil administration showed preferential pulmonary vasodilator effect of tadalafil. The same finding was reiterated by the PVR-to-SVR ratio, which is independent of oxygen consumption. Hence, this limitation is unlikely to change the study results significantly.
Conclusions
The present study is the first to assess the hemodynamic effects of PDE-5 inhibitors in a group of ES patients. Preliminary evaluation of tadalafil has shown efficacy and safety in selected ES patients, warranting further investigation in this subgroup of patients.
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